<DOC>
	<DOCNO>NCT01786239</DOCNO>
	<brief_summary>This 16-week placebo-control study look investigate whether patient schizophrenia two year less may benefit omega-3 supplement .</brief_summary>
	<brief_title>Omega-3 Dietary Supplements Schizophrenia</brief_title>
	<detailed_description>This study look investigate whether patient schizophrenia 2 year less may benefit omega-3 supplement . The main hypothesis test study white matter integrity assess diffusion tensor imaging ( DTI ) erythrocyte membrane omega-3 concentration may provide mean identify patient likely derive clinical benefit omega-3 supplementation . To test hypothesis investigator enroll 58 patient recent-onset schizophrenia 16-week long randomize double blind placebo-controlled study risperidone versus risperidone plus omega-3 supplementation . Study assessments consent include baseline MRI MRI final visit , blood-work , clinical interview ass symptom , medical assessment side effect . DTI exams peripheral omega-3 concentration obtain prior initiation treatment primary outcome measure total Brief Psychiatric Rating Scale Score . Specific aim : - To examine efficacy omega-3 fatty acid adjuvant agent treatment patient recent-onset schizophrenia . The investigator hypothesize patient treat omega-3 fatty acid demonstrate great Brief Psychiatric Rating Scale ( BPRS ) reduction compare placebo group . - To identify whether pre-treatment fractional anisotropy ( FA ) assess DTI predict patient derive clinical benefit omega-3 fatty acid . The investigator hypothesize patient low fractional anisotropy derive great clinical benefit omega-3 fatty acid supplementation . - To identify whether pre-treatment peripheral omega-3 fatty acid concentration predict patient derive clinical benefit omega-3 fatty acid . The investigator hypothesize patient low peripheral omega-3 fatty acid concentration derive great clinical benefit omega-3 fatty acid supplementation .</detailed_description>
	<mesh_term>Disease</mesh_term>
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Bipolar Disorder</mesh_term>
	<mesh_term>Psychotic Disorders</mesh_term>
	<mesh_term>Mental Disorders</mesh_term>
	<mesh_term>Risperidone</mesh_term>
	<criteria>Current DSMIVdefined diagnosis schizophrenia , schizophreniform , schizoaffective disorder , psychosis NOS Bipolar I assess use Structured Clinical Interview Axis I DSMIV Disorders ; Does DSMIV criteria current substanceinduced psychotic disorder , psychotic disorder due general medical condition , delusional disorder , brief psychotic disorder , share psychotic disorder , mood disorder psychotic feature ; current positive symptom rat 4 ( moderate ) one BPRS item : conceptual disorganization , grandiosity , hallucinatory behavior , unusual thought content ; early phase illness define take antipsychotic medication cumulative lifetime period 2 year less ; age 15 40 ; competent willing sign inform consent ; woman , negative pregnancy test agreement use medically accept birth control method . serious neurological endocrine disorder medical condition treatment know affect brain ; medical condition require treatment medication psychotropic effect ; significant risk suicidal homicidal behavior ; cognitive language limitation , factor would preclude subject provide informed consent ; medical contraindication treatment risperidone ( e.g . neuroleptic malignant syndrome prior risperidone exposure ) , omega3 supplement ( e.g . bleed disorder , seafood allergy ) placebo capsule ( e.g . allergy capsule component ) ; contraindication MRI imaging ( e.g . presence pacemaker ) ; lack response prior adequate trial risperidone ; take omega3 supplement within past 8 week , require treatment antidepressant mood stabilize medication .</criteria>
	<gender>All</gender>
	<minimum_age>15 Years</minimum_age>
	<maximum_age>40 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Adolescence</keyword>
	<keyword>Adult</keyword>
	<keyword>Antipsychotic Agents</keyword>
	<keyword>Female</keyword>
	<keyword>Human</keyword>
	<keyword>Male</keyword>
	<keyword>Risperidone</keyword>
	<keyword>Omega-3</keyword>
	<keyword>Schizophrenia</keyword>
	<keyword>Schizophreniform</keyword>
	<keyword>Schizoaffective</keyword>
	<keyword>Schizophrenia -- *drug therapy</keyword>
</DOC>